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 ABBREVIATIONS 
 
HDL-C High-density lipoprotein-cholesterol 
LDL-C Low-density lipoprotein-cholesterol 
VLDL-C Very low-density lipoprotein-cholesterol 
IDL-C Intermediate-Indensity lipoprotein-cholesterol 
TC Total cholesterol  
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 INTRODUCTION 
DYSLIPIDEMIA  
Dyslipidemia means an abnormal amount of lipids, or fats, in the blood. Lipids are 
essential to life, but an excess of certain lipids can increase the risk for cardiovascular 
disease.Disorders of the metabolism of lipoproteins including lipoprotein over-production and 
deficiency are classified as Dyslipidemias. 
The lipids that are commonly measured in blood include various forms of cholesterol, as 
well as triglycerides. High-density lipoprotein (HDL) is the “good cholesterol,” and higher levels 
reduce the risk of cardiovascular disease. Low-density lipoprotein (LDL) is the “bad 
cholesterol,” linked to increased risk of heart attacks and strokes. High triglycerides are also a 
risk factor for cardiovascular disease. 
In dyslipidemia, the level of one or more of these lipids is abnormal (either too high or 
too low). Increased activity and a healthy diet should be the first course of treatment for 
dyslipidemia. If you are at risk for heart attack or stroke, and diet and exercise fail to bring high 
lipid levels into the healthy range, your doctor may recommend taking a lipid-lowering medicine 
CLASSIFICATIONS OF DYSLIPIDEMIA 
• Primary Dyslipidemia 
  These can be familial or genetic due to single gene effect or multiple genetic, 
dietary and physical activity related causes. 
• Secondary Dyslipidemia 
  These forms of Dyslipidemia are a consequence of other conditions such as 
associated diseases and use of drugs.  
EPIDEMIOLIGY 
Coronary heart disease (CHD) is one of the primary causes of morbidity and mortality in 
Western countries.[1] Every year, 7.2 million people die from CHD worldwide, more than from 
 cancer or infectious causes. In the United States alone, 640,000 deaths can be attributed to 
CHD.[2] 
Main causes of Dyslipidemia are.  
• Genetic predisposition (tendencies to run in families) 
• Diabetes 
• Obesity 
• Sedentary life styles 
• Fatty food consumption 
• Hypothyroidism (deficiency state of thyroid gland) 
• Hyperhomocystinemia (increased levels of homocystine levels in blood)  
• Smoking and Alcohol intake 
What affects cholesterol levels?  
A variety of things can affect cholesterol levels. These are things you can 
do something about: 
Diet: 
 ¾ Saturated fat and cholesterol in the food you eat make your blood cholesterol level 
go up.  
 ¾ Saturated fat is the main culprit, but cholesterol in food also matters.  
 ¾ Reducing the amount of saturated fats and cholesterol in diet helps lower your blood 
cholesterol levels. 
 
 Weight: 
 ¾ Being overweight is a risk factor for heart disease.  
 ¾ It also tends to increase your cholesterol. 
 ¾ Losing weight can help lower L and total cholesterol levels, well as raise your HDL 
and lower your triglyceride levels. 
 
 
Physical activity: 
 ¾ Not being physically active is a risk factor for heart disease.  
  ¾ Regular physical activity can help lower LDL (bad) cholesterol and raise HDL 
(good) cholesterol levels. 
 ¾ It also helps you lose weight.  
 ¾ You should try to be physically active 30 minutes on most, if not all days. 
 
Age and Gender: 
 ¾ As women and men get older, there cholesterol levels rise.  
 ¾ Before the age of menopause, women have lower total cholesterol levels than men of 
same age.  
 ¾ After the age of menopause, women's LDL levels tend to rise. 
  
Heredity: 
¾ Your genes partly determine how much cholesterol your body makes. 
¾  High blood cholesterol can run in families.[3] 
 
PATHOPHYSIOLOGY OF DYSLIPIDEMIA 
The response to injury hypothesis states that risk factors such as 
y oxidized LDL 
y mechanical injury to the endothelium, 
y excessive homocystien, 
y immunologic attack or 
y infection-induced changes in endothelial and intimal function lead to endothelial 
dysfunction and a series of cellular interactions 
 
  
                   Cholesterol Homeostasis  
Cholesterol is a lipid that serves primarily as a precursor to steroid hormones and bile
acids, and as the main component of cell membranes. Sources of cholesterol needed to carry out
normal life functions are manufactured by the body and ingested from exogenous dietary
sources. Cholesterol levels in the blood reflect approximately 40% to 60% endogenous
cholesterol, with the balance coming from dietary sources. Triglycerides, which are composed of
fatty acids esterified to glycerol and used as energy substrates, are supplied by fats in the diet and
through the conversion of carbohydrates by the liver. 
Cholesterol, triglycerides, and other lipids in the body are transported through the
bloodstream in spherical particles called lipoproteins. Lipoproteins can be divided into five major
categories depending on their composition. The classes from largest and least dense to smallest 
and most dense are chylomicrons, very-low-density lipoprotein (VLDL), intermediate-density 
lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). The 
larger, more buoyant particles primarily have a triglyceride-rich core, while the smaller, more 
dense particles have a cholesterol ester core.[4] LDL accounts for approximately 60% to 70% of 
total serum cholesterol and is the primary atherogenic class of lipoproteins. HDL constitutes
approximately 20% to 30% of total serum cholesterol with VLDL comprising about 10% to
15%.[5],[6] 
Cholesterol/Lipoprotein Classes 
Total Cholesterol: This represents the total serum cholesterol. 
Triglycerides (TGs): Lipids carried through the bloodstream to tissues. Most of the body’s fat
tissue is in the form oftriglycerides, stored for use as energy. Triglycerides are obtained primarily
from fat in foods. 
Chylomicrons: A small fat globule composed of protein and lipid (fat). Chylomicrons are found 
in the blood and lymphaticfluid where they serve to transport fat from its port of entry in the
intestine to the liver and to adipose tissue. 
Very low density lipoproteins (VLDLs): Lipoproteins that are rich in triglycerides, produced in 
 the liver, and are the majorcarriers of endogenous (produced by the body) triglycerides 
Low-density lipoproteins (LDL): The final-stage lipoprotein from the catabolism of VLDLs. 
LDLs is the primary carrier ofcholesterol in the body. Intermediate density lipoproteins (IDL) are 
a subfraction of LDLs. LDLs are commonly knownas the ‘‘bad’’ cholesterol because they
contribute to the buildup of plaque within the arteries. There are 7 different sizesof LDLs. The
smaller, denser LDLs are more atherogenic. 
High-density lipoproteins (HDL): HDLs are composed of a high proportion of protein with
little triglyceride andcholesterol. HDLs are involved in reverse cholesterol transport, which is
believed to protect against heart disease and stroke. HDLs are commonly known as the ‘‘good’’ 
cholesterol because they help keep cholesterol from building up inthe arteries. There are different
subfractions of HDLs: HDL2 and HDL3. HDL2 is the subfraction that appears to beprotective
against heart disease.[7] 
Cholesterol is derived from two sources: exogenously from the systemic circulation and
endogenously via intracellular synthesis.[8],[9] The exogenous lipoprotein system is responsible 
for the synthesis, transportation, and catabolism of chylomicron particles and 
remnants.Saturated, monounsaturated, and polyunsaturated fats and cholesterol esters digested
and absorbed in the proximal small bowel are reformulated and packaged into chylomicrons by
cells in the intestinal endothelium.Thus, chylomicrons are primarily composed of fatty acids, 
cholesterol, and apolipoproteins that are obtained from the diet. These chylomicrons then enter
the lymphatic system and travel through the body until they are broken down by the enzyme
lipoprotein lipase in the capillary beds to chylomicron remnants, which are smaller, contain less 
fatty acids, but have retained apolipoproteins B-48 and E. These remnants are then cleared from 
the circulation by the LDL-related receptor protein found in the liver. 
  
 
 
 
 Cholesterol homeostasis and transport in humans. Schematic for the 
endogenous and exogenous pathways of cholesterol synthesis and transport. 
 
FIGURE:1 
 
  
          In addition to replenishing their cholesterol pools by taking up circulating lipoproteins
from exogenous sources, cells can also synthesize their own cholesterol through the endogenous
pathway. The intracellular synthesis of cholesterol involves a series of biochemical reactions
starting with acetyl-CoA. The rate-limiting enzymes involved in this process are HMG-CoA 
synthetase, which catalyzes the conversion of acetyl- CoA to HMG-CoA, and HMG-CoA 
reductase, which catalyzes the conversion of hepatic HMG-CoA to mevalonic acid, used in a 
later step in the biosynthesis of cholesterol. The statins, or HMG-CoA reductase inhibitors, 
competitively inhibit this enzyme, reducing the capacity of the cell to synthesize cholesterol.[10] 
  
FIGURE:2 
 
 
 
 Fatty acids and cholesterol produced by the body are then transported through the
endogenous pathway. Three major lipoproteins are involved in this pathway: VLDL, LDL, HDL.
Triglycerides can be synthesized by the liver, especially in the presence of excess carbohydrates,
and later secreted into the bloodstream as VLDL. These VLDL particles contain approximately 
five times more triglycerides than cholesterol, and also contain apolipoproteins B-100, E, and C-
II. The B and E proteins link with B-E or LDL cell surface receptors, while apolipoprotein C-II 
functions as a cofactor for the enzyme lipoprotein lipase. Once secreted into the bloodstream, 
triglyceride molecules are hydrolyzed from the VLDL particles by lipoprotein lipase, located in
the capillary beds. On release, these free fatty acids are used for energy production primarily by
heart and skeletal muscle, or stored in fat cells. Nonetheless, this process of lipolysis decreases
the triglyceride content and size of the VLDL particles, preparing them for either of their two
known metabolic fates: clearance via the hepatic remnant receptor, or further release of 
triglycerides resulting in the formation of IDL particles. 
IDL particles are high in triglyceride content, and contain almost all of the cholesterol
initially contained in the VLDL particles. Lipolysis continues through the actions of lipoprotein
lipase and hepatic lipase, leading to much smaller, cholesterol-rich LDL particles. By this time, 
apolipoproteins E and C have been removed, leaving only apolipoprotein B-100 on the LDL 
particles. IDL particles are intermediate products between VLDL and LDL particles and 
therefore have a short life span. Their cholesterol and triglyceride contents do not significantly
impact cholesterol measurements. Except for rare dyslipidemias, less than 5% of cholesterol
circulates in IDL particles. Half of these IDL particles are cleared from the circulation by the 
LDL receptor while the other half is converted to LDL particles. 
LDL is the primary atherogenic lipoprotein, and the smaller the size of the LDL particle,
the more it is able to penetrate into subendothelial tissue, where it contributes to the development 
of atherosclerosis. Excessive circulating LDL cholesterol will cause cholesterol deposition
outside of the cell, causing atherogenic plaque formation in the vascular endothelium, potentially
leading to coronary artery disease (CAD).Two specific types of LDL particles have recently been
identified to be highly associated with HD risk. The first, a lipoprotein(a) [Lp(a)] particle, is a
very small LDL particle surrounded by a plasminogen-like protein. The other subclass of small, 
dense LDL particles is referred to as atherogenic lipoprotein phenotype B. This subclass is found
 in approximately 30% of the population and is associated with a high risk of CHD. 
The third major lipoprotein involved in the endogenous pathway is HDL. Similar to LDL 
particles, HDL particles are rich in cholesterol and very small. However, HDL particles appear to
be involved in reverse cholesterol transport, resulting in an antiatherogenic effect. Specifically,
HDL may prevent or remove cholesterol deposits within the arterial wall. Other possible
explanations for the beneficial role of HDL cholesterol include the following:  
1) prevents LDL oxidation by working as an antioxidant 
2) reduces platelet aggregability by increasing prostacyclin production 
3) stabilizes serum prostacyclin and promotes fibrinolysis 
4) competitively inhibits the uptake of LDL by endothelial cells  
5) prevents LDL aggregation and uptake by macrophages  
6) decreases cholesterol and foam cell formation 
7) inhibits platelet activation by LDL through the phosphatidylinositol cycle. 
        An important function of HDL is that it can serve as a marker for abnormal metabolism of
chylomicrons and VLDL particles, because as triglycerides increase, HDL decreases. 
        Two key enzymes are involved in the transport of cholesterol from the periphery to the
liver, where it can be eliminated by HDL particles. Lecithin-cholesterol acyltransferase is 
responsible for converting the cholesterol in HDL particles into insoluble cholesterol esters,
causing them to partition in the core of these lipoproteins. The other enzyme, cholesterol ester
transfer protein, is involved in the transfer of cholesterol esters from HDL particles to
triglyceride-rich particles in exchange for triglyceride molecules. Once in VLDL and IDL 
particles, cholesterol is transported to the liver for elimination. 
          All three lipoproteins are highly involved in the transport of triglycerides and cholesterol
from the liver to the body where they may be used by cells, and from the body to the liver where 
they may be eliminated. If the amount of cholesterol is insufficient to meet the requirements of
any cell, the cell will up-regulate its synthesis of the LDL receptor. The newly formed LDL
receptor will migrate to an area on the surface of the cell called the coated pits. Once in the 
coated pits, the cell is capable of recognizing circulating lipoproteins that contain either
 apolipoprotein E or B (VLDL, IDL, and LDL particles). Both the VLDL and IDL particles
contain both B and E proteins and therefore may have a higher binding affinity for the LDL
receptor than the LDL particles. Once binding occurs, the lipoproteins are internalized by the
cell, taken up by liposomes, and broken down into elemental substances to be used by the cell.
The LDL receptor protein returns to the cell surface where it can bind with another circulating
lipoprotein, repeating the process again. 
         Link Between Cholesterol and CHD 
The processes by which lipids and lipoproteins participate in atherosclerotic plaque 
formation and CHD events continue to be an area of controversy and research. One of the
initiating events of atherosclerotic plaque formation appears to be the entrance of lipoproteins
LDL and Lp(a) into the subendothelial space with their oxidatively modified free radicals 
produced by smooth muscle cells, activated macrophages, and endothelial cells. These
oxidatively modified lipoproteins enter macrophages through a scavenger receptor pathway,
ultimately yielding lipid-rich foam cells. Circulating monocytes are also attracted to smooth 
muscle and endothelial cells by chemoattractant that is augmented by the oxidatively modified
lipoproteins. 
As the macrophage scavenger receptor continues to uptake oxidatively modified
lipoproteins, foam cells continue to form and progress to the next level of atherogenesis, which is
the formation of the fatty streak. At the same time, smooth muscle cells migrate into the
subendothelial space and begin proliferating within the intima, contributing to the overall
atherogenic process. As the process continues, lesions continue to grow by increased smooth
muscle cell proliferation and collagen synthesis. At this point, necrosis of the foam cell and
formation of an extracellular lipid core occurs, as long as plasma LDL levels are elevated. The 
final phase appears to involve an autoimmune inflammatory response that causes T lymphocyte
infiltration of the adventitia (the outermostconnective tissue covering of a vessel). This
inflammatory response appears to complete the process of plaque formation that is the 
underlying culprit in CHD. 
 
 FIGURE:3 
National Cholesterol Educational Program Guidelines 
y Total cholesterol 
<200mg/dL                                    Desirable 
200-239mg/dL                               Borderline high 
>240mg/dL                                    High 
y High Density Lipoprotiens 
<40mg/dL                                       Low 
>60mg/dL                                      High 
y Low Density Lipoprotiens 
<100mg/dL                                    Optimal 
100-129mg/dL                               Near optimal 
130-159mg/dL                              Borderline high 
 160-189mg/dL                              High 
>190mg/dL                                   Very high 
y Triglycerides 
<150mg/dL                                   Normal 
150-199mg/dL                             Borderline high 
200-499mg/dL                             High 
>500mg/dL                                  Very high 
Signs and Symptoms 
• Dyslipidemia itself usually causes no symptoms.[11] 
• Serum lipid levels should be monitored regularly.[12],[13] 
Dyslipidemia can increase the risk of coronary artery disease (CAD) and peripheral arterial 
disease.[14] 
• Symptoms of CAD include angina and dyspnoea.[15] 
• Symptoms of peripheral arterial disease include intermittent claudication (pain, numbness,
aching, or heaviness in the leg muscles during movement and/or cramping in the legs, buttocks,
thighs, calves, or feet).[16] 
• However, both conditions may also be asymptomatic. 
Very high levels of triglycerides (>11.29 mmol/L [>1000 mg/dL]) are a known but rare cause of
pancreatitis in the general population.[17] 
• The initial sign of acute pancreatitis is gradual or sudden pain in the upper abdomen that
sometimes extends through to the back. 
• Other symptoms may include a swollen and tender abdomen, nausea and vomiting, fever,
and tachycardia.[18] 
 Diagnosis 
• Serum lipid profile (measured total cholesterol, TG, and HDL cholesterol and calculated
LDL cholesterol and VLDL. 
Dyslipidemia is suspected in patients with characteristic physical findings or complications
of dyslipidemia (eg, atherosclerotic disease). Primary lipid disorders are suspected when patients
have physical signs of dyslipidemia, onset of premature atherosclerotic disease (at < 60 yr), a 
family history of atherosclerotic disease, or serum cholesterol > 240 mg/dL (> 6.2 mmol/L).
Dyslipidemia is diagnosed by measuring serum lipids. Routine measurements (lipid profile) include
total cholesterol (TC), TGs, HDL cholesterol, and LDL cholesterol. 
Lipid profile measurement: TC, TGs, and HDL cholesterol are measured directly; TC and TG
values reflect cholesterol and TGs in all circulating lipoproteins, including chylomicrons, VLDL,
intermediate-density lipoprotein (IDL), LDL, and HDL. TC values vary by 10% and TGs by up 
to 25% day-to-day even in the absence of a disorder. TC and HDL cholesterol can be measured
in the nonfasting state, but most patients should have all lipids measured while fasting for
maximum accuracy and consistency. 
Testing should be postponed until after resolution of acute illness, because TGs increase
and cholesterol levels decrease in inflammatory states. Lipid profiles can vary for about 30 days
after an acute MI; however, results obtained within 24 h after MI are usually reliable enough to 
guide initial lipid-lowering therapy. 
LDL cholesterol values are most often calculated as the amount of cholesterol not
contained in HDL and VLDL. VLDL is estimated by TG ÷ 5 because the cholesterol
concentration in VLDL particles is usually 1/5 of the total lipid in the particle. Thus, LDL 
cholesterol = TC − [HDL cholesterol + (TGs ÷ 5)] (Friedewald formula). This calculation is
valid only when TGs are < 400 mg/dL and patients are fasting, because eating increases TGs.
The calculated LDL cholesterol value incorporates measures of all non-HDL, nonchylomicron 
cholesterol, including that in IDL and lipoprotein (a) [Lp(a)]. LDL can also be measured directly
using plasma ultracentrifugation, which separates chylomicrons and VLDL fractions from HDL
and LDL, and by an immunoassay method. Direct measurement may be useful in some patients
 with elevated TGs, but these direct measurements are not routinely necessary. The role of apo B 
testing is under study because values reflect all non-HDL cholesterol (in VLDL, VLDL 
remnants, IDL, and LDL) and may be more predictive of CAD risk than LDL alone. 
Other tests: Patients with premature atherosclerotic cardiovascular disease, cardiovascular 
disease with normal or near-normal lipid levels, or high LDL levels refractory to drug therapy
should probably have Lp(a) levels measured. Lp(a) levels may also be directly measured in
patients with borderline high LDL cholesterol levels to determine whether drug therapy is 
warranted. C-reactive protein and homocysteine measurement may be considered in the same
populations. 
Tests for secondary causes of dyslipidemia—including measurements of fasting glucose, liver 
enzymes, creatinine, thyroid-stimulating hormone (TSH), and urinary protein—should be done in 
most patients with newly diagnosed dyslipidemia and when a component of the lipid profile has
inexplicably changed for the worse. 
Screening: A fasting lipid profile (TC, TGs, HDL cholesterol, and calculated LDL cholesterol) 
should be obtained in all adults ≥ 20 yr and should be repeated every 5 yr. Lipid measurement
should be accompanied by assessment of other cardiovascular risk factors, defined as 
• Diabetes mellitus 
• Cigarette use 
• Hypertension 
• Family history of CAD in a male 1st-degree relative before age 55 or a female 1st-degree 
relative before age 65 
A definite age after which patients no longer require screening has not been established,
but evidence supports screening of patients into their 80s, especially in the presence of
atherosclerotic cardiovascular disease. 
Indications for screening patients < 20 yr are atherosclerotic risk factors, such as diabetes,
hypertension, cigarette smoking, and obesity; premature CAD in a parent, grandparent, or 
sibling; or a cholesterol level > 240 mg/dL (> 6.2 mmol/L) or known dyslipidemia in a parent. If
 information on relatives is unavailable, as in the case of adopted children, screening is at the
discretion of the health care practitioner. 
Patients with an extensive family history of heart disease should also be screened by
measuring Lp(a) levels.[19] 
Screening  Recommendations - full fasting lipid profile 
 
Men All men ≥ 40 years every 1 - 3 years 
Women All women postmenopausal and/or ≥ 50 years every 1 – 3 
years 
Children Family history of severe hypercholesterolemia or 
chylomicronemia 
Adults (≥ 18 years) All adults at any age with the following additional risk 
factors or at the discretion of physician 
• Exertional chest discomfort, dyspnea, or erectile 
dysfunction 
• Cigarette smoking - current or within past year 
• Abdominal obesity - waist: men > 102 cm or women > 88 
cm (lower cut-offs are appropriate in South & East Asians) 
• Family history of premature coronary artery disease 
(CAD) 
• Manifestations of hyperlipidemia e.g., xanthelasma, 
xanthoma, corneal arcus 
• Diabetes mellitus (DM) 
• Hypertension (HTN) 
• Chronic kidney disease GFR < 30 mL/min/1.73m2 
• Systemic lupus erythematosus 
• Evidence of atherosclerosis 
  
             Management 
           Nonpharmacologic Treatment 
 
Lifestyle 
 
Smoking 
Cessation 
Results in a 36% reduction in the relative risk of mortality from CAD. 
Diet ↓ saturated and trans fats 
↓ simple sugars and refined carbohydrates 
↑ fruits and vegetables 
↑ whole-grain cereals 
↑ proportion of mono- and 
polyunsaturated oils, including omega-3 fatty acids 
OptimalWaist 
Circumference 
< 94 cm (37 in) for men 
< 80 cm (32 in) for women 
Differs by ethnicity with lower cut-offs appropriate for South and East 
Asians. 
Optimal BMI < 25 kg/m
2
 
Exercise 30 min. daily moderate physical activity[20]
 
Initiation of drug therapy should be considered after 6 months of lifestyle modification. Although
drug therapy is started, lifestyle modifications should be continued to enhance pharmacotherapy. 
In patients with severe dyslipidemia where the clinician does not feel that lipid levels will be
normalized through diet alone, pharmacologic treatment may be initiated sooner. Clinical
assessments of patients must be individualized even if it means deviating from the standard 
guidelines set by the NCEP.[21] 
 
 PHARMACOLOGICAL MANAGEMENT: 
HMG-Co A  Reductase Inhibitors 
• Atorvastatin,  Simvastatin,  Lovastatin, Pravastatin and Rosuvastatin. 
Bile Acid Binding Resins 
• Cholestyramine, Colestipol and Colesevelam 
Activators of Lipoprotein Lipase 
• Gemfibrozil, Bezofibrate and Fenofibrate 
Inhibitors of  lipolysis and triglyceride synthesis 
• Niacin 
Inhibitor of Intestinal Absorption of Cholesterol 
• Ezetimibe and  Gugulipid. 
           HMG-CoA Reductase Inhibitors (“Statins”) 
The statins, or HMG-CoA reductase inhibitors, have taken a major role in the management of 
dyslipidemia, especially in the treatment of elevated LDL cholesterol. More specifically, this
family of agents is considered first line for the treatment of hypercholesterolemia in patients who
have failed to adequately respond to dietary therapy.There are currently six FDA-approved 
HMG-CoA reductase inhibitors marketed in the United States. They all work by inhibiting
HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, the 
rate-limiting step in the biosynthesis of cholesterol. After administration, the HMG-CoA 
reductase inhibitors concentrate in the liver, the major site of cholesterol synthesis. All of the 
available HMG-CoA reductase inhibitors have the ability to decrease LDL and triglyceride
levels, while increasing HDL cholesterol. Their main differences lie in their pharmacokinetic
profiles, the amount of lipoprotein alterations, and cost. The statins are well tolerated, and there 
does not appear to be major differences in toxicity or adverse-effect profiles. 
 The HMG-CoA reductase inhibitors are currently used as adjuncts to diet therapy and in
combination with other lipid-altering agents. They are also important in the treatment of 
dyslipidemia in patients with other comorbid conditions, such as diabetes. Experts have defined
the ideal HMG-CoA reductase inhibitor as one that is well absorbed, reaches the liver
unchanged, undergoes complete hepatic transformation, and is excreted via the hepatobiliary
system. In addition, their once-daily dosing intervals, high efficacy, and tolerability with a low
potential for drug interactions are other important criteria.[22] Of the six statins currently 
available, slight differences among them help determine the selection of the most appropriate
statin for each patient. 
Bile-Acid Sequestrants/Resins 
Cholestyramine (Questran) and colestipol (Colestid) are bile-acid–binding resins indicated for 
the treatment of hypercholesterolemia. These agents exchange an anion, usually sodium, for bile
acids in the intestinal tract, forming a nonabsorbable complex. This interrupts the recycling of
bile acids through the enterohepatic circulation, stimulating hepatic cells to convert more of the 
cholesterol pool into bile acids. Up-regulation of the B-E/LDL receptor occurs, enhancing the 
uptake of circulating lipoproteins by hepatic cells, thereby reducing the concentration of
cholesterol. 
Bile-acid sequestrants primarily affect LDL particles, causing an average 15% to 27% 
reduction in total and LDL cholesterol at high doses, and 10% to 23% reduction with 1 to 3
packets or scoops per day. The decrease in LDL appears to reduce the cholesterol content and the
size of the LDL particles. A 7- to 10-year, double-blind, randomized trial compared the effects of 
diet plus cholestyramine with diet plus placebo in 3,806 men without known CHD but an
elevated cholesterol level of at least 265 mg/dL. The occurrence of nonfatal myocardial
infarction or death from CHD was 8.6% in the placebo group as opposed to 7% in the
cholestyramine group, a statistically significant difference.[23] Unfortunately however, resin 
therapy tends to raise triglyceride concentrations about 7% in the short term, and 2% to 3% after
prolonged therapy.Thus, they should be avoided in patients with mixed lipid disorders. 
Cholestyramine and colestipol should be initiated with 1 to 2 doses (packets or scoops) 
 per day, taken anytime without regard to meals. For additional reductions in cholesterol, 4 to 6
packets or scoops may be taken daily. However, most patients cannot tolerate a full therapeutic
dose and usually achieve a significant reduction in cholesterol with 2 to 4 packs per day.
Compliance with the resins is usually less than 50% because of inconvenience and
gastrointestinal distress. Doses can be taken all at once for convenience, but divided doses are
recommended to reduce gastrointestinal effects caused by increased bulk. The most common
adverse effects involve the gastrointestinal tract and include abdominal pain, belching, bloating,
gas, constipation, nausea, and heartburn. These side effects can be reduced by slowly titrating 
dosages so that the patient can accommodate to each dosage, or have the patient increase the
intake of soluble fiber either with dietary changes or supplemental compounds. 
The bile-acid sequestrants have the advantage of low toxicity, no systemic drug-drug 
interactions, and complementary effects on lipoprotein metabolism when added to other
hypolipidemic agents. One should always remember to separate the time of resin administration
from that of other drugs by approximately 2 hours because of the potential for the other drug to
adsorb onto the resin. 
Fibric-Acid Derivatives/Fibrates 
Currently, three fibrates are approved for use in the United States: clofibrate (Atromid-S), 
gemfibrozil (Lopid), and fenofibrate (Tricor). Fibrates primarily lower triglycerides by 
increasing the activity of lipoprotein lipase, which is responsible for the hydrolysis of
triglycerides from VLDL to LDL particles. If the concentration of triglyceride-rich VLDL 
particles is elevated, rapid conversion to smaller IDL and LDL particles by lipoprotein lipase 
may overwhelm the system and cause an increase in LDL cholesterol. However, in individuals
with normal to modestly elevated triglycerides, fibrates may produce a modest reduction in LDL
cholesterol. In addition, fibric-acid derivatives offer the benefit of increasing HDL cholesterol. In
the Helsinki Heart Study, a 5-year, double-blind, placebo-controlled trial, 4,081 asymptomatic 
men with hypercholesterolemia were randomly assigned to receive gemfibrozil600 mg twice 
daily or placebo. A 10% decrease in total cholesterol, 11% decrease in LDL cholesterol, and an
11% increase in HDL cholesterol occurred in patients treated with gemfibrozil, and was
associated with a significant decrease in cardiac events after 5 years of treatment.[24] 
 Clofibrate is rarely used because of a study reporting an increased mortality with
clofibrate use.[25]Gemfibrozil, however, is prescribed at a usual dose of 600 mg twice daily.
Fenofibrate (Tricor) is the most recent FDA-approved fibric- acid derivative, offering 67 mg of 
micronized fenofibrate in each oral capsule. This newly micronized formulation should be
initiated at a dose of 67 mg/day, taken once daily with a meal, and increased gradually to a
maximum dose of 3 capsules/day (201 mg) when necessary after repeat serum triglyceride
estimations at 4 to 8 weeks.[26] Although more direct comparisons are needed, fenofibrate may
decrease LDL cholesterol more than gemfibrozil. Unfortunately, there are no data available on
the effects of fenofibrate on CHD.[27] 
Side effects of the fibrates include myalgias, elevated liver function tests, gastrointestinal
discomfort, and rashes. The most severe side effect is the ability of the fibrates to increase
cholesterol in the bile, which can lead to an increase in gallstone formation. 
Niacin/Nicotinic Acid 
Niacin (Niacor, Nicolar, niacin tablets) is an essential B vitamin that has lipid-regulating 
effects when administered at higher doses. The major mechanism of action appears to be the
decreased release of VLDL, which in turn leads to decreased levels of IDL and LDL in the
endogenous cascade.[10] In addition, niacin appears to reduce cholesterol concentrations through
several mechanisms that include: reducing the hepatic synthesis of apolipoprotein B-containing 
particles, decreasing free fatty acid concentrations by inhibiting adipose tissue lipolysis,
decreasing the synthesis of Lp(a), and decreasing the metabolism of HDL particles. Niacin has
the advantage of increasing HDL cholesterol more than any other agent.[28] Niacin is approved 
for the treatment of hypertriglyceridemia, hypercholesterolemia, and mixed hyperlipidemias. 
To effectively lower lipid levels, niacin should be administered at dosages of 1.5 to 6
grams/day. Niacin reduces both the size and quantity of VLDL particles produced by the liver,
causing the concentration of triglycerides to fall by approximately 20% to 50%. In addition,
niacin can decrease LDL cholesterol by 10% to 25%, and increase HDL cholesterol by 15% to
35%. In the Coronary Drug Project Research Group, a placebo-controlled trial conducted in men 
with previous myocardial infarction, total mortality in the niacin group was significantly reduced
 by 11% at 15-year follow-up, which included almost 9 years after discontinuation of the study 
drug.[29],[30] Although it offers many benefits, the majority of patients receiving niacin experience
one or more side effects, which include flushing, tingling, itching, rash, and headaches, which
are thought to be produced by prostaglandin-mediated vasodilation. To lessen these side effects, 
the dosage should be titrated slowly. Patients are also advised to take niacin with food or with a
dose of 325 mg of aspirin 30 minutes before taking the niacin to reduce the prostaglandin-
mediated vasodilation. Other significant adverse effects that can occur from niacin therapy
include dyspepsia, diarrhea, flatulence, and elevations in blood glucose and uric acid
concentrations. 
Niacin has also been available in a sustained-release formulation to reduce the dosing 
frequency. Sustained-release niacin has been associated with hepatotoxicity, but it appears to be
associated almost exclusively with the older sustained-release formulations.[31] This 
hepatotoxicity appears to be dose-related, most often occurs at daily doses greater than 2 grams, 
and is completely reversible once the drug is discontinued.[32],[33]Several cases of fulminant 
hepatic failure have been reported in patients taking high-dose time-release niacin (>2 
grams/day)[34],[35]. A recent randomized, double-blind, placebo-controlled trial of 223 
hypercholesterolemic patients comparing the newer Niaspan versus plain niacin at a dose of 1.5
grams/day demonstrated no clinically significant hepatic dysfunction.[36] In addition, adverse 
reactions, including general malaise, anorexia, and jaundice, have been reported after an abrupt
change from the immediate- to sustained-release formulation. The dosages of the sustained-
release formulation that caused these adverse effects were well above the usual recommended 
daily dose of 0.25 to 1 gram. There is approximately a threefold to sixfold difference in the upper
limits of the recommended dosages of the sustained-release formulation (1 gram/day) as opposed 
to the immediate-release formulation (3 to 6 grams/day), which may be attributable to the 
differences in metabolic handling of the two formulations. As mentioned previously, niacin can
cause blood glucose levels to rise, and is known to increase uric acid concentrations with the
potential of precipitating gout. In a recent double-blind, placebo-controlled trial of 223 patients 
with hypercholesterolemia, plain niacin increased fasting plasma glucose levels 4.8%, while
Niaspan increased levels by 4.5%. However, uric acid levels increased less, 6% with Niaspan 
versus 16% with plain niacin, a statistically significant difference.[37]Although the results of this 
 study show that Niaspan may be safer for patients with other comorbid conditions, further studies
are needed to evaluate if Niaspan offers any significant benefit over plain niacin for patients with 
diabetes or gout. 
Niacin should be initiated at a dose of 100 mg twice daily for 1 week. If this is tolerated,
the dose is increased to 200 mg twice daily for the following week. If the patient continues to 
tolerate the niacin, the dose is increased to 300 to 400 mg twice daily for 6 weeks. At this time,
the patient should undergo a lipid profile and liver function tests prior to a clinic visit. If the
patient continues to tolerate the niacin, and the lipid panel shows a positive response, the dosage 
is changed to 500 mg twice daily and the patient is reevaluated in 6 to 7 weeks. 
Combination Therapy 
Combination therapy is often necessary in severe cases of dyslipidemia. The introduction of
higher potency statins, such as atorvastatin, has largely decreased the need for combination
therapy to lower LDL levels. However, statins may be combined with a variety of other
hypolipidemic agents to obtain a synergistic effect by using agents that work through different 
mechanisms of action. The most widely used combination regimen involves a statin and a bile-
acid sequestrant, which has been shown to be safe, complementary, cost-effective, and valuable 
in severe hypercholesterolemia.[38],[39] The bile-acid sequestrant will interrupt the enterohepatic 
circulation of the cholesterol-rich bile salt pool, leading to increases in hepatic bile-acid synthesis 
and LDL receptor activity. Increased clearance of LDL from the circulation in conjunction with
increased gastrointestinal loss of cholesterol will stimulate HMG-CoA reductase activity, 
increasing cholesterol synthesis and returning cholesterol levels to normal. This increased
synthesis of cholesterol may be partially inhibited by combining a statin with the resin, resulting 
in an enhanced reduction in LDL.[40] In a recent meta-analysis, combination therapy with 
cholestyramine and a statin (fluvastatin, lovastatin, pravastatin, or simvastatin) produced 
decreases of 55% in LDL, 27% to 43% in total cholesterol, and 2% to 15% in triglycerides. In 
addition, these combinations increased HDL by 7% to 17%. Combination therapy with a statin
and a resin can impact lipid levels more significantly than either agent alone.[41] 
Statins have also been combined with fibric-acid derivatives that act primarily by increased 
 catabolism of triglyceride-rich lipoproteins by stimulating lipoprotein lipase, resulting in
enhanced VLDL degradation. However, if there is also a receptor defect, the increased LDL
generated as an end product may not be cleared from the circulation. Therefore, the combination
of a fibrate and a statin may alleviate this effect. The controversial issue that remains to be
addressed is whether these lipid-lowering benefits outweigh the potential risks of therapy. Both
statins and fibric-acid derivatives have been linked individually to myopathy, and in
combination, they can potentially accentuate this adverse event. However, the incidence of
myopathy in patients taking the combination regimen is less than 1.0%.[42]Therefore, the 
combination of a fibrate and a statin may be used cautiously in patients with mixed lipid
disorders, with a low risk of muscle necrosis. The regimen should be discontinued at the first
sign of muscle ache. 
The combination of niacin 1,500 to 3,000 mg with a statin further reduces LDL by 10% 
to 15%, triglycerides by 10% to 30%, and increases HDL by 9% to 12%. This combination has
the added benefit of reducing atherogenicity by reducing particle size and postprandial remnant
accumulation. There is a risk of hepatic necrosis and rhabdomyolysis using this combination, but
with careful monitoring, the risk is quite low.[43] 
Because atorvastatin has the most powerful LDL-lowering effect, with the added benefit 
of reducing triglycerides, combination therapy may not be necessary. Compliance is often a 
problem when patients are asked to take more medications, and the risk of drug interactions
becomes an issue. Therefore, the treatment of dyslipidemia should always start with lifestyle
modifications. If lipid-lowering responses are inadequate, then pharmacotherapy can be added to
lifestyle modifications, but single drug therapy should always be maximized before the addition
of a second agent to maximize compliance and minimize the chance of drug interactions and cost
issues. 
  
 
 
 
 
 
 Currently Available Lipid-Lowering Medications 
 
 
Generic Name Trade Name
(*generic available) 
Dose  
 
Statins 
Atorvastatin 
Fluvastatin 
Lovastatin 
Pravastatin 
Rosuvastatin 
Simvastatin 
 
Lipitor 
Lescol, LescolXL 
Mevacor * 
Pravachol * 
Crestor 
Zocor * 
 
10 mg - 80 mg 
20 mg - 80 mg 
20 mg - 80 mg 
10 mg - 80 mg 
5 mg - 40 mg 
10 mg - 80 mg 
Bile acid and/or cholesterol absorption 
inhibitors 
Cholestyramine 
Colestipol 
Ezetimibe 
 
 
Questran* 
Colestid 
Ezetrol 
 
 
2 g - 24 g 
5 g - 30 g 
10 mg 
Fibrates 
Bezafibrate 
Fenofibrate 
 
 
 
Gemfibrozil 
 
Bezalip * 
Lipidil 
-Micro* 
-Supra* 
-EZ 
Lopid * 
 
400 mg 
 
67 mg, 200 mg 
100 mg, 160 mg 
48 mg, 145mg 
600mg–1200mg 
Niacins 
Nicotinic acid 
 
 
Crystallineniacin* 
Niaspan 
 
1 g - 3 g 
0.5 g - 2 g 
 
  
1.ATORVASTATIN 
DESCRIPTION:  
Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for 
lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxyl methylglutaryl-
coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via 
the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to 
mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels 
increases hepatic uptake of cholesterol and reduces plasma cholesterol levels. 
STRUCTURAL FORMULA   
CHEMICAL NAME:  
 (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-
pyrrol-1-yl]-3,5-dihydroxyheptanoic acid. 
MOLECULAR FORMULA:  
 C33H35FN2O5 
 
  
 
 
 
 
 
 
CLINICAL PHARMACOLOGY: 
Mechanism of action  
 Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA 
reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in 
the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol 
levels.Decreasedhepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors 
which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations. 
Absorption:  
 Atorvastatin is rapidly absorbed after oral administration with maximum plasma 
concentrations achieved in 1 to 2 hours. The absolute bioavailability of atorvastatin (parent drug) 
is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is 
approximately 30%. The low systemic bioavailability is due to presystemic clearance by 
gastrointestinal mucosa and first-pass metabolism in the liver. 
Volume of distribution: 
 381 L 
MOLECULAR WEIGHT: 
 558.63  
EXPERIMENTAL PROPERTIES:  
Property Value 
melting point 159.2-160.7 °C 
Water solubility Sodium salt soluble in water, 20.4 ug/mL 
(pH 2.1), 1.23 mg/mL (pH 6.0) 
LogP 5.7 
 
 Protein binding: 
 >98% bound to plasma proteins 
Route of elimination:  
 Eliminated primarily in bile after hepatic and/or extrahepaticmetabolism.Does not appear 
to undergo significant enterohepatic recirculation. Less than 2% of the orally administered dose 
is recovered in urine. 
Pharmacodynamics:  
 Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor, is used to lower 
serum total and LDL cholesterol, apoB, and triglyceride levels while increasing HDL 
cholesterol. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated 
with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C 
ratio is a strong predictor of coronary artery disease and high ratios are associated with higher 
risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By 
decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular 
morbidity and mortality. Atorvastatin has a unique structure, long half-life, and hepatic 
selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase 
inhibitors. 
Half life:  
 14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived 
active metabolites 
Toxicity: 
 Generally well-tolerated. Side effects may include myalgia, constipation, asthenia, 
abdominal pain, and nausea. Other possible side effects include myotoxicity(myopathy,myositis, 
rhabdomyolysis) and hepatotoxicity. To avoid toxicity in Asian patients, lower doses should be 
considered. 
 FOOD INTERACTION: 
• Avoid alcohol. 
• Avoid drastic changes in dietary habit. 
• Avoid taking grapefruit or grapefruit juice throughout treatment. Grapefruit can 
significantly  increase serum levels of this product. 
• Food may decrease maximumplasma levels and area under the curve, but this is clinically 
inconsequential according to the manufacturer. 
• Take with low fat meal. 
INDICATION: 
 May be used as primary prevention in individuals with multiple risk factors for coronary 
heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of 
myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to 
reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May 
be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous 
familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an 
adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-
C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density 
lipoprotein cholesterol (HDL-C) levels. 
 
DOSAGE FORMS:  
Dosage forms Route strength 
Tablet Oral 10mg 
Tablet Oral 20mg 
Tablet Oral 40mg 
Tablet Oral 80mg 
 
 2.FENOFIBRATE 
DESCRIPTION:  
 An antilipemic agent which reduces both cholesterol and triglycerides in the blood.  
STRUCTURAL FORMULA: 
 
 
CHEMICAL NAME:  
 propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate 
MOLECULAR FORMULA:  
 C20H21ClO 
MOLECULAR  WEIGHT: 
  360.831 
 
 
 EXPERIMENTAL PROPERTIES: 
 
 
Route of 
Property Value 
melting point 80.5 °C 
 Water solubility 0.25mg/ml at 25 °C 
logP 5.3 
 
 
CLINICAL PHARMACOLOGY: 
Mechanism of action 
Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated 
receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from 
plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The 
resulting fall in triglycerides produces an alteration in the size and composition of LDL from 
small, dense particles, to large buoyant particles. These larger particles have a greater affinity for 
cholesterol receptors and are catabolized rapidly. 
Absorption:  
 Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate 
is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric 
acid glucuronide 
Volume of distribution 
• 95 L [moderate renal impairment (creatinine clearance of 50 to 90 mL/min)] 
• 30 L [healthy adults] 
Protein binding: 
 ~99% (Serum protein binding) 
 Elimination:  
 Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. 
Following oral administration in healthy volunteers, approximately 60% of a single dose of 
radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate 
conjugate and 25% was excreted in the feces. 
Pharmacodynamics:  
 Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce 
elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with 
primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). 
Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with 
hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active 
metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, 
apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. 
In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and 
apoproteinsapoAI and apoAII. 
Half life:  
 20 hours 
Clearance: 
 1.2 L/h [Eldery] 
Toxicity:  
 LD50=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard. 
FOOD INTERACTIONS:   
 Increased absorption- take with meals. 
INDICATION: 
          For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and 
Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed 
dyslipidemia.[44] 
 LITERATURE REVIEW 
 
• Paul M. Lavigne, et al., in 2013 had done a study on the Current State of Niacin in 
Cardiovascular Disease Prevention a Systematic Review and Meta-Regression. This study 
sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as 
indicated by the aggregate body of clinical trial evidence including data from the recently 
published AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low 
HDL/High Triglycerides: Impact on Global Health Outcomes) trial. Clinical trials of niacin, 
alone or combined with other lipid-altering therapy, were identified via MEDLINE. Odds 
ratios (ORs) for CVD endpoints were calculated with a random-effects meta-analyses.Meta-
regression modeled the relationship of differences in on-treatment high-density lipoprotein 
cholesterol with the magnitude of effect of niacin on CVD events.The conclusion shows the 
consensus perspective derived from available clinical data supports that niacin reduces CVD 
events and, further, that this may occur through a mechanism not reflected by changes in 
high-density lipoprotein cholesterol concentration. 
 
• Robert Krysiak, et al., in 2011 studied the effect of Simvastatin and Fenofibrate on 
Cytokine Release and Systemic Inflammation in Type 2 Diabetes Mellitus With Mixed 
Dyslipidemia. compare the effect of simvastatin and fenofibrate treatment on the secretory 
function of human monocytes and lymphocytes and on systemic inflammation in type 2 
diabetes and to assess whether their coadministration is superior to treatment with only 1 of 
these drugs. The conclusion shows simvastatin and fenofibrate exhibit a similar effect on the 
secretory function of human monocytes and lymphocytes and on systemic inflammation in 
type 2 diabetic subjects with mixed dyslipidemia. This effect may be clinically relevant in the 
prevention of vascular complications in metformin- and diet-treated subjects with newly 
diagnosed diabetic dyslipidemia. 
  
• Carl J Fichtenbaum, et al., in 2010 performed a Treatment with pravastatin and fenofibrate 
improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. Statins and 
fibrates alter lipids, apolipoproteins, and inflammatory markers in persons without HIV.The 
conclusion Treatment with pravastatin or fenofibrate improves the atherogenic lipid profile 
 within the first 12 weeks and is sustained through 48 weeks with combination therapy. 
Adiponectin levels decrease with lipid-lowering therapy. However, markers of inflammation 
and platelet activation were not appreciably changed suggesting that the biologic properties 
of these agents differ in persons with HIV infection. 
 
• M. John Chapman, et al.,in 2010 had done a study on  atherogenic dyslipidemia using 
Niacin and fibrates: Pharmacotherapy to reduce cardiovascular risk. statin therapy represents 
a cornerstone of cardiovascular disease (CVD) prevention, a major residual CVD risk (60–
70% of total relative risk) remains, attributable to both modifiable and non-modifiable risk 
factors. Among the former, low levels of HDL-C together with elevated triglyceride (TG)-
rich lipoproteins and their remnants represent major therapeutic targets. The current 
pandemic of obesity, metabolic syndrome, and type 2 diabetes is intimately associated with 
an atherogenicdyslipidemic phenotype featuring low HDL-C combined with elevated TG-
rich lipoproteins and small dense LDL. Niacin is distinguished by its unique capacity to 
effectively lower Lp(a) levels. Several studies have demonstrated anti-atherosclerotic action 
for both niacin and fibrates. In contrast with statin therapy, the clinical benefit of fibrates 
appears limited to reduction of nonfatal myocardial infarction, whereas niacin (frequently 
associated with statins and/or other agents) exerts benefit across a wider range of 
cardiovascular endpoints in studies involving limited patient numbers. Clearly the future 
treatment of atherogenic dyslipidemias involving the lipid triad, as exemplified by the 
occurrence of the mixed dyslipidemic phenotype in metabolic syndrome, type 2 diabetes, 
renal, and auto-immune diseases, requires integrated pharmacotherapy targeted not only to 
proatherogenic particles, notably VLDL, IDL, LDL, and Lp(a), but also to atheroprotective 
HDL. 
 
• Anne C. Goldberg, et al., in 2009had done a study on Efficacy and Safety of ABT-335 
(Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia. In 
patients with mixed dyslipidemia characterized by increased triglycerides (TG), decreased 
high-density lipoprotein (HDL) cholesterol, and increased low-density lipoprotein (LDL) 
cholesterol, monotherapy with lipid-altering drugs often fails to achieve all lipid targets. 
Combination therapy was generally well tolerated with a safety profile consistent with those 
 of ABT-335 and atorvastatin monotherapies. No rhabdomyolysis was reported. The 
conclusion shows ABT-335 + atorvastatin combination therapy resulted in more effective 
control of multiple lipid parameters than either monotherapy and may be an appropriate 
therapy for patients with mixed dyslipidemia. 
  
• Peter H. Jones, et al., in 2009 had done a study on Efficacy and safety of fenofibric acid in 
combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 
3, 12-week randomized, controlled studies. In patients with mixed dyslipidemia, combination 
therapy simultaneously improved multiple lipid abnormalities more effectively than 
fenofibric acid or statin monotherapies. Combination therapy was generally well tolerated, 
and safety profiles were similar to monotherapies. 
 
• Sonja V Sorensen, et al., in 2009 had done a study on Model-based simulation to explore 
the cost-effectiveness of following practice guidelines for triglyceride and low-density 
lipoprotein cholesterol control among patients with diabetes mellitus and mixed 
dyslipidemia. The National Cholesterol Education Program Adult Treatment Panel III 
guidelines recommend maintaining lipid levels within particular targets to reduce the risk of 
coronary heart disease (CHD) events. A simulation model using a US health care payer 
perspective was designed to predict changes in lipid levels (LDL-C, TG, high-density 
lipoprotein cholesterol, and total cholesterol) and long-term CHD risk. The results of this 
model simulation suggest that for patients with DM and mixed dyslipi-demia, following 
treatment guidelines rather than current practice (including combination therapy rather than 
monotherapy) would result in more patients achieving lipid targets, fewer CHD events, and 
more QALYs gained at a reasonable cost (less than $109,000) per QALY. 
 
• Sergio Fazio, et al., in 2008 had done a study on management of mixed dyslipidemia in 
patients with or at risk for cardiovascular disease. Lowering low-density lipoprotein 
cholesterol (LDL-C) is the primary focus of the management of dyslipidemia in patients with 
or at risk for cardiovascular disease. The addition of fenofibrate to statin therapy may be a 
useful strategy for the management of mixed dyslipidemia in patients with or at risk for 
cardiovascular disease. 
 • Gloria Lena Vega, et al., in 2006 had done a study on Combination of fenofibrate plus low-
dose nicotinic acid added to statin treatment in type 2 diabetes. Plasma lipid abnormalities 
commonly persist in patients with diabetic dyslipidemia in spite of statin monotherapy. 
Fenofibrate plus low-dose nicotinic acid adequately improves the lipoprotein profile in 
patients with diabetic dyslipidemia who are being treated with a statin. Plasma levels of total 
cholesterol, triglycerides, very-low-density lipoprotein plus intermediate-density lipoprotein 
cholesterol (VLDL+IDL-C), low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol (HDL-C), and apolipoprotein B were also measured. The conclusion shows that 
reatment with the 3-drug regimen was associated with a significant reduction in triglyceride 
levels compared with simvastatin monotherapy. However, there was not a significant 
incremental reduction in triglyceride levels when nicotinic acid was added to the 2-drug 
treatment, suggesting that the triglyceride-lowering effect of fenofibrate + nicotinic acid is 
not cumulative. To obtain clinically meaningful responses, particularly for the treatment of 
elevated HDL-C, higher doses of nicotinic acid might be required. 
 
• FD Richard Hobbs, et al., in 2006 explained about the Reduction of cardiovascular risk in 
diabetes: Beyond glycemic and blood pressure control. Patients with diabetes mellitus have a 
much higher rate of cardiovascular disease (CVD) than the general population, and, in 
addition to glycaemia and hypertension, dyslipidemia has emerged as an important 
modifiable cardiovascular risk factor in these patients. In most patients with type 2 diabetes, 
the major features of dyslipidemia are increased triglyceride levels, decreased high-density 
lipoprotein cholesterol (HDL-C) levels, and changes in the composition and level of low-
density lipoprotein cholesterol (LDL-C). Clinical trials evaluating both primary and 
secondary prevention of CVD demonstrate that lipid-lowering therapy results in a substantial 
reduction of cardiovascular risk in patients with type 2 diabetes. Low-density lipoprotein 
cholesterol is the first priority for treatment, with a statin in adequate dosage as the first 
choice for pharmacological therapy. The first statin trial conducted solely in patients with 
type 2 diabetes and no prior CVD demonstrated a 37% reduction in cardiovascular events in 
patients randomized to atorvastatin 10 mg compared with placebo. Additional trials that 
further address the benefits of lipid-lowering therapy in patients with diabetes are near 
 completion, or are underway, and should provide important information about further 
attenuating risk in patients with diabetes. 
  
• Michael H. Davidson, et al., in 2005 had done a study on Efficacy and safety profile of 
fenofibrate-coated microgranules 130 mg, with and without food, in patients with 
hypertriglyceridemia and the metabolic syndrome. The limited bioavailability of certain 
fenofibrate formulations necessitates administration with food, raising concerns about 
efficacy and compliance. There is a need for new formulations that have improved 
bioavailability and eliminate the requirement for administration with food.The conclusion 
shows that this study found no inequivalence in the TG-lowering effects of the 2 fenofibrate 
regimens compared with placebo. Both regimens were well tolerated. Thus, FF-μG 130 mg 
administered without regard to meals appears to be efficacious and well tolerated for the 
treatment of hypertriglyceridemia in patients exhibiting the metabolic syndrome. 
   
• Robert S Rosenson, et al., in 2005 studied the new approaches in the intensive management 
of cardiovascular risk in the metabolic syndrome .The risk factors such as dyslipidemia and 
hypertension are inadequately controlled in subjects with the metabolic syndrome by lifestyle 
interventions, pharmacologic approaches are warranted. Statins are first-line 
pharmacotherapy for dyslipidemia due to their efficacy for lowering low-density lipoprotein 
(LDL) cholesterol and may also improve high-density lipoprotein (HDL) cholesterol and 
triglyceride levels. Fibrates and niacin may be useful in combination with a statin for 
additionally lowering triglycerides or raising HDL cholesterol. Adequate control of 
hypertension will usually require two or more drugs; agents that block the renin-angiotensin 
system are particularly useful in this population, given their demonstrated benefits for 
reducing the burden of cardiovascular events and end-stage renal disease independent of 
blood-pressure lowering. A multifaceted approach to risk factor management for the 
metabolic syndrome will have benefits for prevention of type 2 diabetes and cardiovascular 
disease. 
 
• Verny C, et al., in 2005 explained the management of dyslipidemia in elderly diabetic 
patients. The prevalence of diabetes increases with age, potentially affecting 20% of the 75 
 years and older elderly population. Overmortality and increased cardiovascular morbidity-
mortality are common in diabetic populations, including elderly diabetes. This increased 
cardiovascular risk must therefore be taken into consideration when discussing management 
of dyslipidemia in elderly diabetics. Should dyslipidemia be treated in elderly diabetics? 
What are the objectives and with what means? Whether the significance of dyslipidemia is 
different in this growing population compared with younger subjects remains unknown due 
to the lack of specific studies. The only results available come from a few primary or 
secondary cardiovascular prevention trials using statins or fibrates with subgroups of elderly 
diabetic patients, or subgroups of diabetic patients and also subgroups of patients aged over 
65. Three recent studies detailed the potential benefit of such treatment: PROSPER in elderly 
subjects aged 70-82 years, HPS in diabetics before and after the age of 70 years and CARDS 
in diabetics aged up to 75 years. The results of these studies provide a few indirect elements 
of interest, keeping in mind the generally higher iatrogenic risk of treatment in elderly 
populations. 
 
• Giuseppe Derosa,et al., in 2004 had done a study on Comparison of fluvastatin + fenofibrate 
combination therapyandfluvastatinmonotherapy in the treatment of combined 
hyperlipidemia,type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, 
double-blind, controlled trial. Diabetes risk is often complicated by a mixed 
hyperlipoproteinemia not sufficiently controlled by a single antihyperlipidemic drug; 
however, there are some concerns about the safety of combined statin and fibrate treatments. 
The conclusion shows that the  patients with combined hyperlipidemia, type 2 DM, and 
CHD, the combination of extended-release fluvastatin + micronized fenofibrate was 
associated with a more improved lipid profile than fluvastatinmonotherapy, and was a well-
tolerated and cost-effective therapeutic choice to treat these patients at high risk for CVD. 
 
• Antonios M Xydakis, et al., in 2002 had done a study on Combination therapy for combined 
dyslipidemia.Patients with combined dyslipidemia are at high risk for coronary artery disease 
and often require combination drug therapy to achieve lipid levels recommended by the US 
National Cholesterol Education Program’s third Adult Treatment Panel (ATP III). In addition 
to recommendations for low-density lipoprotein (LDL) cholesterol and triglyceride levels, 
 ATP III established non–high-density lipoprotein (HDL) cholesterol goals for individuals 
with triglycerides ≥2.26 mmol/L (≥200 mg/dL). It also introduced certain criteria for the 
diagnosis of the metabolic syndrome, a clustering of risk factors (abdominal obesity, elevated 
triglycerides, low HDL cholesterol, elevated blood pressure, impaired fasting glucose) that 
increases cardiovascular risk and is common in patients with combined dyslipidemia. Statin 
monotherapy has been shown to benefit these patients, and additional benefit may be 
obtained by combination therapy that provides greater reductions in both LDL cholesterol 
and triglycerides as well as greater increases in HDL cholesterol. Recently developed agents 
that may improve the effectiveness of combination therapy include ezetimibe—a cholesterol 
absorption inhibitor—and a formulation that combines extended-release niacin and lovastatin 
in a single pill. Clinical trials are needed to determine the optimal treatment in patients with 
combined dyslipidemia. 
  
• Michael H Davidson, et al., in 2002 had done a study on Combination therapy for 
dyslipidemia: safety and regulatory considerations. The use of combination therapy is an 
effective way to manage dyslipidemia in patients with coronary artery disease (CAD). 
Aggressive lipid-altering therapy often requires the use of combination therapy involving 
statins in conjunction with niacin, fibric-acid derivatives, ezetimibe, or bile acid resins. Yet, 
safety concerns regarding the combination of statins with other lipid-altering drugs and 
patient acceptance of combination therapy have influenced its application in the treatment of 
CAD.   
   
• Peter H Jones, et al., had done a study on Efficacy and safety of ABT-335 (fenofibric acid) 
in combination with rosuvastatin in patients with mixed dyslipidemia. The conclusion shows 
that patients with mixed dyslipidemia, combination therapy with ABT-335 + rosuvastatin 
resulted in more effective control of multiple lipid parameters than either monotherapy alone, 
with a safety profile similar to both monotherapies.  
 
• Jadwiga Najib, et al., had done a study onFenofibrate in the treatment of dyslipidemia: A 
review of the data as they relate to the new suprabioavailable tablet formulation. The fibric 
acid derivative fenofibrate is indicated as an adjunct to dietary modification in adults with 
 primary hypercholesterolemia or mixed dyslipidemia (types IIa and IIb hyperlipidemia, 
Fredrickson classification) to reduce levels of low-density lipoprotein cholesterol (LDL-C), 
total cholesterol (TC), triglycerides (TG), and apolipoprotein (apo) B, and to increase levels 
of high-density lipoprotein cholesterol (HDL-C) and apo A. Fenofibrate is effective in 
reducing levels of TG, TC, and LDL-C, and increasing levels of HDL-C in patients with 
dyslipidemias. Its efficacy and tolerability in the treatment of hypertriglyceridemia and 
combined hyperlipidemia have been demonstrated in numerous clinical trials. Its use is 
accompanied by a low incidence of adverse effects and laboratory abnormalities. Fenofibrate 
protects against coronary heart disease not only through its effects on lipid parameters but 
also by producing alterations in LDL structure and, possibly, alterations in the various 
hemostatic parameters. Its uricosuric property may prove to be a useful adjunctive attribute 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 AIM AND OBJECTIVES 
  
AIM  
 The aim of the study is to evaluate and compare the efficacy and safety of Atorvastatin 
alone and in combination with Fenofibrate in Dyslipidemic patients at Dharmapuri, Tamilnadu.  
 
OBJECTIVE 
y To evaluate and compare the efficacy of atorvastatin as monotherapy alone and as                        
combination therapy with fenofibrate. 
y To evaluate and compare the safety of atorvastatin alone and in combination with 
fenofibrate. 
y To compare the efficacy of both therapies among male and female dyslipidemic patients. 
y To compare the efficacy of both therapies on diabetic and non-diabetic dyslipidemic 
patients. 
 
 
 
 
 
 
 
 
 
 PLAN OF THE WORK 
 
 The entire study was planned to be carried out for a period of a ten months from 
December 2012 to August 2013. 
 The proposal was designed as given below. 
 
PROPOSAL 
December – January 2013  
y Literature survey. 
y Obtaining Consent from the hospital authority. 
y Study design including design of data entry form. 
 
Feb – June 2013 
y Selection of Patients. 
y Obtaining consent from the patients. 
y Collection of Patient Details.  
y Collection of Lab data. 
 
June – August 2013  
y Compilation 
y Data analysis  
y Submission of reports 
 
 
 METHODOLOGY 
   
¾ Site  of  Study : 
  Suba Medical Centre And Hospital, Dharmapuri.  
¾ Department  Selected  for  Study  :  
  Cardiology  department 
¾ Institutional ethics committee approval 
¾ Consent  From  Hospital  Authority  
¾ Study Design 
Institutional ethics committee 
 A protocol of the study, which includes the objectives, methodology, etc, was 
submitted to “Institutional ethics committee” for approval of the study.   
STUDY DESIGN 
 Patient selection 
 Patient groups 
 Design of proforma 
 
Patient Selection 
Patient Inclusion Criteria: 
Patients on dyslipidaemic drugs   
    Both genders 
    Age between 18 to 80 years  
Patients co-morbid conditions such as 
Diabetes Mellitus       
Coronary Artery Disease 
     Myocardial Infarction 
    Hypertension 
Patient Exclusion Criteria 
Pregnant or lactating women 
Patients with any co-morbidity such as  
   Acute emergency hypertensive patients  
   Renal transplant patients 
   Liverdiseased patients 
   Malignant patients 
              Hereditary or acquired myopathy 
              Hypersensitivity to study medications 
 
PatientGroups  
y Patients grouped into two: 
                          Group-A                          Group-B 
  Patients having either high level of LDL-C or TG or both than that of normal 
level were put under the Group A and patients having abnormal level of  LDL-C, TG and HDL-C 
were put under the Group B.  
Group-A: Receiving atorvastatin only (Monotherapy). 
Group-B: Receiving both atorvastatin and fenofibrate (Combination therapy). 
 
No of Patients: 
            Total no of patients: 80 
  Group-A         : 40 patients 
  Group-B          : 40 patients 
 
 WORK METHODOLOGY 
¾ On basis of inclusion and exclusion criteria, totally 80 patients were selected and their  
base line lipid profile values, heart rates, blood pressure fasting blood glucose, plasma 
urea and creatinine and drugs used for the treatment were noted.  
¾ Then the data of the same patients after drug therapy after that is after 6 months were 
taken as the review value. Side effects reported by patients were noted. 
  The values obtained under the base and review  in both the groups were analyzed 
using the suitable statistical methods such as 
 column statistics 
 paired t- test 
  Using the software “graph pad -prism 5 for windows version 5.01” 
 
DESIGNOFPROFORMA 
PROFORMA I         :           PATIENT INFORMED CONSENT FORM 
PROFORMA II        :  PATIENT DETAILS FORM 
PROFORMA III       :  LAB INVESTIGATION CHART 
PROFORMA IV       :          MEDICATION CHART 
PROFORMA V         :  ADVERSE DRUG REACTION FORM 
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TABLE:4 
SOCIAL HABITS OF THE INCLUDED PATIENTS (n=80) 
PERCENTAGE 
 
 
SOCIAL HABITS OF THE INCLUDED PATIENTS (n=80) 
  
S.No Social habits No. of Patients Percent(%) 
1. Tobacco Smoker Only 21 26.25 
2. Alcohol User Only 02 02.50 
3. Tobacco Smoker and 
Alcohol  User 
14 17.50 
4. Tobacco Smoker, Chewer 
and Alcohol User 
15 18.75 
5. Without Any Above Habits 28 35.00 
 Total No. of Patients 80 100 
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 Effect of Atorvastatin Alone and in Combination with Fenofibrate on Lipid 
Parameter of Dyslipidemic Patients 
 
Lipid 
parameters 
Monotherapy 
(n=40) 
Combination therapy 
(n=40) 
 Base    
(mg/dL) 
Review     
(mg/dL) 
Mean % 
Change 
(%) 
Base       
(mg/dL) 
Review      
(mg/dL) 
Mean % 
Change 
(%) 
TC 180.4 
± 
29.81 
151.1 
± 
19.77*** 
-16.24 176.2 
± 
44.86 
148.1 
± 
23.07*** 
-15.95 
TG 168.4 
± 
33.16 
140.5 
± 
33.37** 
-16.57 233.1 
± 
59.66 
153.8 
± 
55.96*** 
-34.02 
HDL-C 39.63 
± 
6.28 
39.88 
± 
5.94 
+0.63 33.67 
± 
7.83 
42.25 
± 
13.83*** 
+25.48 
LDL-C 110.3 
± 
26.64 
83.49 
± 
11.58*** 
-24.4 105.2 
± 
41.19 
77.73 
± 
17.75*** 
-26.11 
VLDL-C 34.96 
± 
8.47 
28.68 
± 
6.91*** 
-17.96 46.27 
± 
11.79 
30.77 
± 
11.21*** 
-33.50 
 
Data presented are Mean ± SD 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t” test 
 
TABLE:8 
 Effect of Atorvastatin Alone on  
Lipid Parameter of Dyslipidemic Patients 
 
Figure presented are Mean ± SE 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t” test 
B – Base, R- Review  
 
 
 
 
 
 
 
 
 
 Effect of Atorvastatin in Combination with Fenofibrate on Lipid Parameter of 
Dyslipidemic Patients 
 
 
 
Figure presented are Mean ± SE 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t”test 
B – Base, R- Review  
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 Effect of Atorvastatin Alone and in Combination with Fenofibrate on Heart 
Rate of Dyslipidemic Patients 
S.No Drug Therapy Base Value 
(beats/min) 
Review Value 
(beats/min) 
Percent 
Change (%)
1. Monotherapy 74.85 
± 
2.94 
74.05 
± 
2.55 
-1.07 
2. Combination 
Therapy 
75.55 
± 
2.55 
74.03 
± 
2.86 
-2.01 
  
Data presented are Mean ± SD 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t” test 
TABLE:9 
 
Effect of Atorvastatin Alone and in Combination with Fenofibrate on Heart 
Rate of Dyslipidemic Patients 
 
 
 
 
 
 
 
 
Figure presented are Mean ± SE 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t”test 
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 Effect of Atorvastatin Alone and in Combination with Fenofibrate on BPof 
Dyslipidemic Patients 
  
Drug Therapy Systolic Diastolic 
Monotherapy 
(n= 40) 
Base 
Value 
Review 
Value 
Percent 
Change 
(%) 
Base 
Value 
Review 
Value 
Percent 
Change 
(%) 
141.6 
± 
15.12 
128.1 
± 
5.87*** 
-9.53 84.0 
±  
7.18 
76.23 
±  
5. 87*** 
-9.25 
Combination 
Therapy  
(n= 40) 
143.1 
± 
11.91 
128.5 
± 
9.85*** 
-10.20 88.2 
± 
7.52 
76.6 
±  
5.73** 
-13.15 
 
Data presented are Mean ± SD 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t” test 
 
TABLE:10 
 
 Effect of Atorvastatin Alone and in Combination with Fenofibrate on 
BPofDyslipidemic Patients 
 
 
Figure presented are Mean ± SE 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t”test 
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Effect of Atorvastatin Alone and in Combination with Fenofibrate on Fasting 
Blood Glucose of Dyslipidemic Patients 
S.No Drug Therapy Base Value 
(beats/min) 
Review 
Value 
(beats/min) 
Percent 
Change(%) 
1. Monotherapy 113.5 
± 
16.32 
114.8 
± 
13.3 
+1.14 
2. Combination Therapy 99.69 
± 
16.97 
97.84 
± 
13.7 
-1.85 
 
Data presented are Mean ± SD 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t” test 
TABLE:11 
 
Effect of Atorvastatin Alone and in Combination with Fenofibrate on Fasting 
Blood Glucose of Dyslipidemic Patients 
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 Effect of Atorvastatin Alone (n=40) and in Combination with Fenofibrate on 
Renal Functions of Dyslipidemic Patients (n=40) After Drug Therapy  
 
S.No Parameters Monotherapy 
(mg/dl) 
Combination Therapy 
(mg/dl) 
Normal 
level 
(mg/dl) 
1. Urea 25.13 28.34 10-40 
2. Creatinine 1.18 1.20 0.7-1.4 
 
TABLE:12 
 
Adverse Drug Reaction of Atorvastatin Alone (n=40) and in Combination 
with Fenofibrate of Dyslipidemic Patients (n=40) 
 
Adverse Reactions Monotherapy Combination 
Therapy 
Rhabdomyolysis 0 2 
Pancreatitis 0 0 
Anthralgia 1 2 
Fatigue 1 0 
Diarrhoea 1 2 
Nausea 2 0 
Headache 3 0 
Depression 0 0 
Memory Loss 0 0 
Confusion 0 0 
Aggressive Reactions 0 0 
TABLE:13 
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 Effect of Atorvastatin alone on Male and Female Dyslipidemic Patients 
Separately (n=40) 
Lipid 
Parameters 
Male (n=27) Female (n=13) 
Base 
(mg/dL) 
Review 
(mg/dL) 
Mean 
% Change 
Base 
(mg/dL) 
Review 
(mg/dL) 
Mean% 
Change 
TC 178.7     
± 
32.66 
150.4 
± 
21.98 *** 
-15.84 183.9 
±  
23.56 
152.6 
±         
14.81*** 
-17.02 
TG 170.8 
± 
35.21 
144.9 
± 
 37.53** 
-15.16 163.4 
± 
29.12 
131.5 
± 
20.93* 
-19.52 
HDL-C 39.43 
± 
5.01 
39.2 
± 
5.99  
-0.58 40.05 
± 
8.57 
41.29 
± 
5.8          
+3.10 
LDL-C 107.7 
± 
27.39 
83.4 
± 
11.5*** 
-22.56 114.6 
± 
25.41 
83.67 
± 
12.22 *** 
-26.99 
VLDL-C 35.33 
± 
9.86 
29.4 
± 
7.88 ** 
-16.78 34.2 
± 
4.69 
27.2 
± 
4.11*** 
-20.46 
  
Data presented are Mean ± SD 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t” test 
 
TABLE:14 
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 Effect of Atorvastatin in Combination with Fenofibrate on Male and Female 
Dyslipidemic Patients Separately (n=40) 
Lipid 
Parameters 
  Male (n=26) Female (n=14) 
Base 
(mg/dL) 
Review 
(mg/dL) 
Mean% 
Change 
Base 
(mg/dL) 
Review 
(mg/dL) 
Mean% 
Change 
TC 175.3 
± 
36.56 
149.5 
± 
25.08** 
-14.72 178 
± 
58.84 
145.5 
± 
19.38* 
-18.26 
TG 232.3 
± 
65.27 
163.2 
± 
64.09*** 
-29.75 234.7 
± 
49.82 
136.3 
± 
31.48 *** 
-41.92 
HDL-C 31.25 
± 
5.8 
40.2 
± 
9.67 *** 
+28.64 38.15 
± 
9.27 
46.05 
± 
19.24* 
+20.70 
LDL-C 106 
± 
34.33 
80.54 
± 
18.55 *** 
-24.02 103.6 
± 
53.11 
72.53 
± 
15.45 * 
-29.99 
VLDL-C 46.63 
± 
12.9 
33.04 
± 
12.68*** 
-29.14 45.6 
± 
9.81 
26.55 
± 
6.21*** 
-41.78 
 
Data presented are Mean ± SD 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t” test 
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 Effect of Atorvastatin Alone on Diabetic and Non-Diabetic Patients (n=40) 
 
Lipid 
Parameters 
Diabetic Patients (n=19) Non-Diabetic Patients (n=21) 
Base 
(mg/dL) 
Review 
(mg/dL) 
Mean% 
Change 
Base 
(mg/dL) 
Review 
(mg/dL) 
Mean% 
Change 
TC 175.1 
± 
30.53 
151.5 
± 
19.06*** 
-13.48 186.3 
± 
28.62 
150.6 
± 
21.03 *** 
-19.16 
TG 175.8 
± 
23.6 
145 
± 
38 ** 
-17.52 160.1 
± 
40.33 
135.5 
± 
27.56* 
-15.36 
HDL-C 37.74 
± 
4.68 
39.32 
± 
6.78     
+4.19 41.72 
± 
7.23 
40.51 
± 
4.96    
-2.9 
LDL-C 103.17 
± 
30.04 
82.82 
± 
10.57  ** 
-19.72 116.9 
± 
20.91 
84.22 
± 
112.86 *** 
-27.95 
VLDL-C 35.17 
± 
4.84 
29.54 
± 
8.05** 
-16.01 34.73 
± 
11.38 
27.74 
± 
5.44  ** 
-20.13 
 
Data presented are Mean ± SD 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t” test 
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 Effect of Atorvastatin in Combination with Fenofibrate on Diabetic and Non-
Diabetic Patients (n=40) 
 
Lipid 
Parameters 
Diabetic Patients (n=27) Non-Diabetic Patients( n=13) 
Base 
(mg/dL) 
Review 
(mg/dL) 
Mean% 
Change 
Base 
(mg/dL) 
Review 
(mg/dL) 
Mean% 
Change 
TC 171.7 
± 
36.99 
147 
± 
17.94 ** 
-14.38 174.9 
± 
53.07 
147.8 
± 
27.08 * 
-15.49 
TG 243.2 
± 
73.29 
158 
± 
64.76 *** 
-35.03 222.2 
± 
37.14 
147.3 
± 
43.62 *** 
-33.71 
HDL-C 33.03 
± 
5.16 
40.17 
± 
7.28 *** 
+21.62 33.54 
± 
9.88 
43.42 
± 
18.05 ** 
+29.46 
LDL-C 102.7 
± 
35.06 
81.43 
± 
16.32 ** 
-20.71 103.1 
± 
46.88 
73.6 
± 
18.08 ** 
-28.61 
VLDL-C 48.62 
± 
14.64 
31.22 
± 
13.08*** 
-35.79 43.53 
± 
6.98 
29.44 
± 
8.7 *** 
-32.37 
 
Data presented are Mean ± SD 
p-value *<0.01; **<0.001; ***<0.0001 vs base group using paried’ ‘t” test 
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 DISCUSSION 
¾ Out of the selected 80 patients,53(66%) patients were Male and 27(34%) patients were 
Female. 
 
¾ 4(5%) patients were in the age group of 31-40 years, 15(19%) patients were in the age group 
of 41-50 years, 24(30%) patients were in the age group of 51-60 years, 29(36%) patients 
were in the age group of 61-70 years, 8(10%) patients were in the age group of 71-80 years. 
 
¾ 21(26%) patients were smoker,2(2.5%) patients were Alcoholic, 14(17.5%) patients were 
both Smoker and alcoholic, 15(19%) patients were smoker, alcoholic and chewer and 
28(35%) patients were neither asmoker, chewer nor alcoholic. 
  
¾ 29(36%) patients were vegetarian and 51(64%) patients were mixed diet. 
 
¾ 29(36%) patients had only Hypertension, 16(20%) patients had only Diabetes mellitus, 
23(29%) patients had both hypertension and diabetes mellitus and 12(15%) patients had no 
hypertension and diabetes mellitus. 
 
¾ 24(30%) patients had family history of coronary artery disease and 56(70%) patients had no 
family history of coronary artery disease 
 
¾ A total of 80 patients were enrolled in the study. They received atorvastatin (n=40) and 
combination of atorvastatin and fenofibrate (n=40) for a period of 6 months.After 6 months 
there was a significant reduction (P < 0.0001) in TC (16%) , TG(16.5%) , LDL-C(24%) , 
VLDL-C(18%) and significant increase in HDL-C  in monotherapy group as compared to 
baseline values. There was a significant reduction (P<0.0001) in TG(34%) , LDL-C(26%), 
VLDL-C(33.5%) except TC and insignificant increase in HDL-C  in combination therapy 
group as compared with baseline values. 
 
¾ Significant changes in TG, HDL-C, LDL-C,VLDL-C were found in the combination therapy 
group (-34%,+25%, -26%, -33.5% respectively) versus the monotherapy group (-16.5%, 
 +0.6%, -24%, -18% respectively; all P<0.0001 between groups). 
 
¾ There was a significant change in heart rate, systolic BP, diastolic BP, fasting blood glucose 
were found in the combination therapy group (-2.01%, -10.2%, -13.15%, -1.85% 
respectively) versus the monotherapy group (-1.07%, -9.53%, -9.25%,+1.14% respectively ; 
all P<0.0001 between groups). 
 
¾ Both treatments were well tolerated, with no significant differences in the incidences of 
adverse events between the Two groups. 
 
¾ The analysis revealed that Group A (monotherapy) each One patient had adverse effects 
ofAnthralgia,fatigue, diarrhoea, Two patients had Nausea and Three patients had Headache. 
 
¾ Group B (Combination therapy) Two patients had adverse effects ofRhabdomyolosis, two 
patients had Anthralgia, and two patients had Diarrhoea. 
 
¾ In both groups none of the patients had not had the adverse effects of Pancreatitis, 
Depression, Memory Loss, Confusion, Aggressive Reactions. 
 
¾ There was a significant change between the male and FemalePatients on the lipid parameters 
in both therapies. 
 
¾ In monotherapy group a total of 40 patients 27 patients were male and 13 patients were 
female. 
 
¾ In the monotherapy group significant reduction (P < 0.0001) in TC (16%) , TG(15%) , LDL-
C(22.5%) , VLDL-C(17%)  in Male patients as compared to baseline values. There was a 
significant reduction (P<0.0001) in TC (17%), TG(19.5%) , LDL-C(27%), VLDL-C(20%)  
and significant increase in HDL-C in Female patients as compared with baseline values. 
 
¾ Significant changes in TC, TG, HDL-C, LDL-C,VLDL-C were found in the  Female patients 
(-17%, -19.5%, +3.1,  -27%, -20% respectively) versus the male patients (-16%, -15%, -0.58,  
-22.5%, -17% respectively; all P<0.0001 between groups). 
 ¾ In Combination therapy group a total of 40 patients 26 patients were male and 14 patients 
were female. 
 
¾ In the Combination therapy group significant reduction (P< 0.0001) in TC (15%), TG(30%) , 
LDL-C(24%) , VLDL-C(29%) in Male patients as compared to baseline values. There was a 
significant reduction (P<0.0001) in TC (18%), TG(50%) , LDL-C(30%), VLDL-C(42%)  and 
significant increase in HDL-C  in Female patients as compared with baseline values. 
 
¾ Significant changes in TC, TG, HDL-C, LDL-C,VLDL-C were found in the  Female patients 
(-18%, -50%, +20.7,  -30%, -42% respectively) versus the male patients (-15%, -30%, 
+28.64,  24%, -29% respectively; all P<0.0001 between groups). 
 
¾ There was a significant improvement between the Diabetic and non-diabetic patients in both 
the therapies. 
 
¾ In monotherapy group out of 40 patients 19 patients were Diabetic patients and 21 patients 
were Non-diabetic patients. 
 
¾ In the monotherapy group significant reduction (P < 0.0001) in TC (13.4%) , TG(17.5%), 
LDL-C(20%) , VLDL-C(16% )and insignificant increase in HDL-C  in Diabetic patients as 
compared to baseline values. There was a significant reduction (P<0.0001) in TC (19%), 
LDL-C(28%), VLDL-C20(%) except TG and insignificant decrease in HDL-C  in Non-
diabetic  patients as compared with baseline values. 
 
¾ Significant changes in TC, LDL-C,VLDL-C were found in the Non-diabetic  patients (-19%, 
-28%, -20% respectively) versus the Diabetic  patients (-13.4% , -20%, -16% respectively; all 
P<0.0001 between groups).The observed difference in a decrease in TG and change in HDL-
C was not statistically significant between the Diabetic  and  Non-diabetic  patients. 
 
¾ In the combination therapy group out of 40 patients 27 patients were diabetic patients and 13 
patients were Non-diabetic patients. 
 
 
 ¾ In the Combination therapy group significant reduction (P < 0.0001) in TC (14%), TG(35%), 
HDL-C(21.6%), LDL-C(20.7%) , VLDL-C(35.8%) in Diabetic patients as compared to 
baseline values. There was a significant reduction (P<0.0001) in TC (15%), HDL-C(29%), 
LDL-C(28.6%) except TG and VLDL-C  in Non-diabetic  patients as compared with baseline 
values. 
 
¾ Significant changes in TC, HDL-C, LDL-C, were found in the Non-diabetic patients (-15%, 
+29%, -28.6% respectively) versus the Diabetic patients (-14%, +21.6%, -20.7 %, 
respectively; all P<0.0001 between groups). The observed difference in a decrease in TG, 
VLDL-C was not statistically significant between the Diabetic and Non-diabetic  patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 
¾ On comparing the gender-wise it was found that the improvement of lipid profile was better 
in case of female patients in both monotherapy and combination therapy compared to male 
patients. 
  
¾ On comparing the diabetic and  non-diabetic dyslipidemic patients it was found that the 
improvements of non-diabetic patients were slightly higher than that of diabetic patients in 
both therapies. 
  
The therapeutic aspects of the study can be concluded as 
Dyslipidemia is characterized by increased low-density lipoprotein cholesterol (LDL-C), 
elevated Triglycerides(TG), and decreased High-density lipoprotein cholesterol (HDL-C). It is 
more common in diabetes and associated with increased risk of  Coronary artery disease. 
 Atorvastatin therapy was effective to the patients with high level of TC, TG, LDL-C and 
VLDL-C. 
 Patients with high level of TC, TG, LDL-C and VLDL-C and low levels of HDL-C were 
effectively treated with atorvastatin along with fenofibrate than the normal level. 
 The combination therapy (atorvastatin along with fenofibrate) was more effective thanthat of 
monotherapy (atorvastatin). 
 Monotherapy with statins or Fibrates may not effectively control all lipid parameters. 
 The atorvastatin-fenofibratecombination  had been shown to have highly beneficial effect on 
lipid parameters in diabetes associated with dyslipidemia. 
 Both the therapies were safe. 
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 PROFORMA -I  
INFORMED CONSENT FORM 
 
Patient  Name :       Patient ID: 
Age                :       Date      : 
Sex                 :   
 
  I was explained about the description of the research study and they have 
answered allthe questions I have at this time. I have been toldthat there are no risks and only  
benefits associated with participating in this study. 
  Ifreely volunteertoparticipate in this study. I understand that I need not have to 
take part in this study and that my refused to participate will involve no penalty. Further I 
understand that I am free to discontinueparticipationfromthis study at any time. 
 
 
 
 
 
 Clinician’s Name :      Patient’s Signature :  
 
 
      
      PROFORMA- II 
PATIENT DETAILS FORM 
 
Patient Id:                                                                          Patient Name: 
Age:                                                                                   Sex: 
Height:                                                                               Weight:                                   
Consultant name:-Dr.  
Review on:  
Diagnosis: 
Complaints: 
Past medical history:                              
Past medication history:      
Social history: 
                             Nonalcoholic/alcoholic: 
Non smoker/smoker: 
                             Vegetarian/non vegetarian: 
Present medication history:  
Family history: 
Any other associated diseases:   
 
 
 
 PROFORMA- III 
PATIENT’S LAB  INVESTIGATION CHART 
 
Patient Name :       Patient ID: 
Age                :       Date      : 
Sex                 :     
 
Parameters Base line Review I 
Lipid Profile 
Total Cholesterol 
Triglycerides 
HDL-C 
LDL-C 
VLDL-C 
Fasting Glucose level 
Heart Rate 
Blood Pressure 
Systolic 
Diastolic 
Renal Function Tests 
Urea  
Creatinine 
  
 
 
 
 PROFORMA- IV 
MEDICATION CHART 
Patient Name :       Patient ID: 
Age                :       Date      : 
Sex                 :    
 
S.No. No.of days Medications Dose/ Frequency Time Route 
1.      
 
2.      
3.      
4.      
5.      
6.      
7.      
8.      
9.      
10.      
 
 
 
 
 PROFORMA- V 
ADVERSE DRUG REACTION FORM 
Patient Name :       Patient ID: 
Age                :       Date      : 
Sex                 :    
 
ADVERSE EFFECTS REVIEW 
Rhabdomyolysis 
Pancreatitis 
Anthralgia 
Fatigue 
Diarrhoea 
Nausea 
Headache 
Depression 
Memory Loss 
Confusion 
Aggressive Reactions 
 
 
  
